Elanco Animal Health (5EA) AI Stock Analysis

Elanco Animal Health

(Frankfurt:5EA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthBroad-based organic growth, supported by volume and pricing, indicates continued demand for Elanco’s animal-health portfolio. Raised full-year guidance provides evidence that momentum is expected to persist beyond one quarter, strengthening the company’s medium-term revenue foundation.

Negative Factors

Persistent Net LossesRevenue and gross-margin improvement have not yet translated into consistent bottom-line profitability. Continued negative net margin and ROE limit internal earnings accumulation, reduce returns on the equity base, and leave execution on product growth and cost control especially important.

Elanco Animal Health (5EA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 11.52B
Dividend Yield: ―
Average Volume (3M): 436
Price to Earnings (P/E): -56.2
Beta (1Y): 0.79
Revenue Growth: 4.41%
EPS Growth: -142.94%
Country: Germany
Employees: 9,650
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Elanco Animal Health Business Overview & Revenue Model

Company Description

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, includin...

Elanco Animal Health Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-8.19%|Next Earnings Date:Nov 05, 2026

Earnings Call SentimentPositive

The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.

Positive Updates

Reported and Organic Revenue Growth

Second quarter revenue of $1.368 billion, up 10% reported and 8% organic on a constant currency basis (driven by +6% volume and +2% price). Full-year revenue guidance raised to $5.09B–$5.14B with organic constant currency growth guidance increased to 6%–7% (from 5%–7%).

Negative Updates

International Farm Animal Softness and Timing Impact

International Farm Animal grew only 2% organic constant currency in Q2, with management citing timing of certain shipments (primarily to the Middle East) as a headwind versus stronger year-to-date growth (7%).

Company Guidance

Elanco raised its full‑year outlook, now targeting 6–7% organic constant‑currency revenue growth with total revenue of $5.09–$5.14 billion (including a ~$60M FX tailwind and ~1 ppt reported growth from the AHV acquisition); adjusted EBITDA of $1.01–$1.035 billion (≈13% growth at the midpoint) and adjusted EPS of $1.10–$1.16 (≈20% growth at the midpoint). Management also increased 2026 innovation revenue to about $1.25 billion, expects ~50 bps of full‑year gross‑margin expansion (and ~75 bps improvement in adjusted EBITDA margin year‑over‑year), aims for year‑end net leverage of ~3x (Q2 was 3.1x), and reiterated Elanco Ascend’s $200–$250 million adjusted‑EBITDA savings goal by 2030. For Q3 the company guided revenue of $1.195–$1.22 billion (organic cc growth 5–7%), adjusted EBITDA around $215 million and adjusted EPS $0.19–$0.22, noting ~11% YoY OpEx growth to support launch and DTC investments.

Elanco Animal Health Risk Analysis

Elanco Animal Health disclosed 46 risk factors in its most recent earnings report. Elanco Animal Health reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Elanco Animal Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5EA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAHC	73Outperform	$1.58B	15.80	28.67%	1.23%	17.12%	106.40%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:5EA and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	DE:5EA	Elanco Animal Health	20.30	0.85	4.39%
	PAHC	Phibro Animal Health Corp	38.88	-3.96	-9.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Elanco Animal Health AI Stock Analysis